Evidence map›Paper›PMID 33407641›Full record

ArticleJournal of neuroinflammation2021

Acute IL-1RA treatment suppresses the peripheral and central inflammatory response to spinal cord injury.

Abi G Yates, Trisha Jogia, Ellen R Gillespie, Yvonne Couch, Marc J Ruitenberg, Daniel C Anthony

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Lesion level and severity acutely influence metabolomic profiles in spinal cord injury.Journal of neuropathology and experimental neurology · 2026
    Article
  6. Review
  7. Review
  8. Inhibition of the RNA Regulator HuR Mitigates Spinal Cord Injury by Potently Suppressing Post-Injury Neuroinflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 4 countries.

Abi G YatesDepartment of Pharmacology, The University of Oxford, Mansfield Road, Oxford, UK.
Trisha JogiaSchool of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia, Queensland, Australia.
Ellen R GillespieSchool of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia, Queensland, Australia.
Yvonne CouchAcute Stroke Programme, RDM-Investigative Medicine, The University of Oxford, Oxford, UK.
Marc J RuitenbergSchool of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia, Queensland, Australia.
Daniel C AnthonyDepartment of Pharmacology, The University of Oxford, Mansfield Road, Oxford, UK. daniel.anthony@pharm.ox.ac.uk.ORCID http://orcid.org/0000-0003-1380-6655
The University of Queensland · AUMansfield University · USUniversity of Oxford · GB

Funding

Medical Research Council MC_PC_15029
6 · The paper itself

Abstract

backgroundThe acute phase response (APR) to CNS insults contributes to the overall magnitude and nature of the systemic inflammatory response. Aspects of this response are thought to drive secondary inflammatory pathology at the lesion site, and suppression of the APR can therefore afford some neuroprotection. In this study, we examined the APR in a mouse model of traumatic spinal cord injury (SCI), along with its relationship to neutrophil recruitment during the immediate aftermath of the insult. We specifically investigated the effect of IL-1 receptor antagonist (IL-1RA) administration on the APR and leukocyte recruitment to the injured spinal cord.

methodsAdult female C57BL/6 mice underwent either a 70kD contusive SCI, or sham surgery, and tissue was collected at 2, 6, 12, and 24 hours post-operation. For IL-1RA experiments, SCI mice received two intraperitoneal injections of human IL-1RA (100mg/kg), or saline as control, immediately following, and 5 hours after impact, and animals were sacrificed 6 hours later. Blood, spleen, liver and spinal cord were collected to study markers of central and peripheral inflammation by flow cytometry, immunohistochemistry and qPCR. Results were analysed by two-way ANOVA or student's t-test, as appropriate.

resultsSCI induced a robust APR, hallmarked by elevated hepatic expression of pro-inflammatory marker genes and a significantly increased neutrophil presence in the blood, liver and spleen of these animals, as early as 2 hours after injury. This peripheral response preceded significant neutrophil infiltration of the spinal cord, which peaked 24 hours post-SCI. Although expression of IL-1RA was also induced in the liver following SCI, its response was delayed compared to IL-1β. Exogenous administration of IL-1RA during this putative therapeutic window was able to suppress the hepatic APR, as evidenced by a reduction in CXCL1 and SAA-2 expression as well as a significant decrease in neutrophil infiltration in both the liver and the injured spinal cord itself.

conclusionsOur data indicate that peripheral administration of IL-1RA can attenuate the APR which in turn reduces immune cell infiltration at the spinal cord lesion site. We propose IL-1RA treatment as a viable therapeutic strategy to minimise the harmful effects of SCI-induced inflammation.

Indexed as

Acute-Phase ReactionAnimalsFemaleHumansImmunity, CellularInflammationInjections, IntraperitonealInterleukin 1 Receptor Antagonist ProteinMiceMice, Inbred C57BLSpinal Cord InjuriesThoracic VertebraeTreatment OutcomeInterleukin 1 Receptor Antagonist ProteinAcute phase responseIL-1 receptor antagonistMacrophageNeurotraumaNeutrophilsSystemic inflammatory response syndrome

Identifiers

PMID33407641
PMCPMC7788822
OpenAlexW3118248510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.